glp-1 for metabolic syndrome Agonists Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH Frontiers | GLP-1/GIP dual agonist

Int J Inf Dis 100:327332

A review found that GLP-1 therapy helped reduce liver fat content and inflammation, showing promise in managing NAFLD even in non-diabetic patients

Achievements and Limits of Current Medical Therapy of Glaucoma

Eduardo Caballero y Caballero

doi: 10.3389/fendo.2019.00376 Received 01 April 2019 Accepted 28 May 2019 Published 19 June 2019 Volume 10 - 2019 Edited by Pierre De Meyts, Catholic University of Louvain, Belgium Reviewed by Alain Couvineau, Institut National de la Sant et de la Recherche Mdicale (INSERM), France

By 2025, cosmetic formulators and wellness brands that adopt this technology early will stand at the forefront of the anti-aging revolution